Torsdag 5 Juni | 03:27:28 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-12 08:00 Kvartalsrapport 2025-Q3
2025-07-18 08:00 Kvartalsrapport 2025-Q2
2025-05-22 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2025-05-21 - Årsstämma
2025-05-21 - Kvartalsrapport 2025-Q1
2025-02-19 - Bokslutskommuniké 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-10 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2024-05-08 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-20 - Bokslutskommuniké 2023
2024-01-04 - Extra Bolagsstämma 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-04 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2023-05-03 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2023-02-13 - Extra Bolagsstämma 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2022-05-19 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-15 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-23 - Årsstämma
2021-05-21 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2021-05-20 - Kvartalsrapport 2021-Q1
2021-05-14 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-06-25 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2020-06-24 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-05-05 - Extra Bolagsstämma 2020
2020-02-19 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2019-05-23 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-26 - Bokslutskommuniké 2018
2018-12-17 - Extra Bolagsstämma 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-16 - Kvartalsrapport 2018-Q1
2018-05-04 - X-dag ordinarie utdelning ISOFOL 0.00 SEK
2018-05-03 - Årsstämma
2018-02-20 - Bokslutskommuniké 2017
2017-11-20 - Kvartalsrapport 2017-Q3
2017-08-21 - Kvartalsrapport 2017-Q2
2017-05-16 - Årsstämma
2017-05-16 - Kvartalsrapport 2017-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Isofol Medical är ett forskningsbaserat bioteknikbolag som arbetar för att förbättra prognosen för patienter med svåra former av cancer. Bolagets läkemedelskandidat arfolitixorin syftar till att höja effekten av första linjens standardbehandling som globalt används vid flera former av solida tumörer. Isofol bedriver klinisk utveckling av arfolitixorin inom kolorektalcancer, världens tredje vanligaste cancerform, där det medicinska behovet av bättre behandlingar är stort.
2025-06-03 08:00:00

GOTHENBURG, Sweden, June 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company is participating in the yearly scientific conference ASCO in Chicago, US, and in connection with this, held an Advisory Board meeting gathering the company’s scientific advisors.

The information in the press release is intended for investors.

Isofol participates in the yearly conference of the American Society of Clinical Oncology (ASCO) held in Chicago, USA, between May 30 and June 3. ASCO is a world-leading oncology conference aiming to spread scientific findings to physicians and researchers within the field of oncology treatment, setting the agenda for future treatments.

In connection to the visit in Chicago, the inaugural meeting was held with Isofol’s newly established Advisory Board, consisting of Dr. Takayuki Yoshino, chairman of the Japan Society of Clinical Oncology; Prof. Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center & Kerck School of Medicine, U.S.; and Prof. Sebastian Stintzing, Charité Universitätsmedizin – Berlin, Germany and study coordinator of the ongoing phase Ib/II trial. At the meeting, the advisors discussed the global development program, preparations for the previously announced Pre-IND-meeting with the U.S. Food and Drug Administration (FDA) as well as the Japanese equivalent PMDA.

ASCO brings together the most prominent cancer experts in the world, an excellent platform to launch our new advisory board. I am particularly pleased that these high-profile experts have chosen to collaborate with us – all are global leaders in their field and their support is highly valuable to Isofol,” says Petter Segelman Lindqvist, CEO of Isofol.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST, on June 3, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com